Cambio de paradigma en el EGFR mutado: desde las primeras mutaciones a las de resistencia - page 22

CNS metastases in EGFR-mut pts

•

In pts with EGFR-mut, incidence of brain metastases 45%, LM 10%

•

Less use of WBRT, long term toxicity

•

AURA 3 including CNS metastases

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,12,13,14,15,16,17,18,19,20,21 23,24,25,26,27,28,29,30,31,32,...35